Bailard Inc. Acquires 157 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Bailard Inc. lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 672,909 shares of the biopharmaceutical company’s stock after purchasing an additional 157 shares during the period. Gilead Sciences accounts for approximately 1.6% of Bailard Inc.’s portfolio, making the stock its 12th biggest holding. Bailard Inc. owned 0.05% of Gilead Sciences worth $62,157,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Bellevue Group AG grew its position in Gilead Sciences by 18.2% during the third quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock worth $3,859,000 after buying an additional 7,093 shares in the last quarter. Quantinno Capital Management LP grew its position in Gilead Sciences by 149.5% during the third quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock worth $6,843,000 after buying an additional 48,910 shares in the last quarter. McAdam LLC grew its position in Gilead Sciences by 16.7% during the fourth quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company’s stock worth $2,344,000 after buying an additional 3,627 shares in the last quarter. Capital Investment Advisors LLC grew its position in Gilead Sciences by 2.6% during the fourth quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock worth $35,793,000 after buying an additional 9,791 shares in the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its position in Gilead Sciences by 3.9% during the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 142,167 shares of the biopharmaceutical company’s stock worth $13,132,000 after buying an additional 5,382 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on GILD shares. Maxim Group downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Mizuho lifted their price objective on Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price objective for the company from $80.00 to $120.00 in a report on Tuesday, February 18th. Wolfe Research assumed coverage on Gilead Sciences in a report on Friday, November 15th. They set an “outperform” rating and a $110.00 price objective on the stock. Finally, Daiwa America raised Gilead Sciences to a “hold” rating in a report on Monday, November 18th. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $102.08.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 8,500 shares of the company’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $91.96, for a total transaction of $781,660.00. Following the completion of the sale, the chief financial officer now owns 132,373 shares in the company, valued at approximately $12,173,021.08. The trade was a 6.03 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders sold 293,356 shares of company stock worth $29,166,240. Insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Performance

GILD stock opened at $114.31 on Friday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The company has a 50 day moving average price of $97.42 and a 200 day moving average price of $90.05. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $114.77. The stock has a market capitalization of $142.46 billion, a PE ratio of 308.95, a price-to-earnings-growth ratio of 0.71 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.76%. The ex-dividend date of this dividend is Friday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s payout ratio is 854.05%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.